About the P. vivax information hub
Tafenoquine featured this year as a key innovation in a UHC special report.
Video on life-changing treatment to cure relapsing P. vivax malaria.
The Malaria in Pregnancy (MiP) Library now available on WWARN.
About 8.5 million people are at risk of malaria in Nepal. Despite this progress, there was a 20% increase from 2016 to 2017.
In this study, the prevalence and distribution of G6PD mutations were investigated across Ethiopia with the goal to provide additional information relevant to the use of primaquine in malaria treatment.
This tool assesses the cost-effectiveness of using G6PD RDTs prior to the administration of primaquine.
The vivax after falciparum Study Group was formed in March 2018, with an invitation to interested researchers with relevant data sets.
TDR invites expressions of interest for membership on its Scientific and Technical Advisory Committee (STAC).
With the increased interest in malaria elimination, TBV and monoclonal antibodies have moved to the center stage of malaria vaccine development. Methodologies to prioritize and evaluate products are urgently needed.
This recent event of large-scale re-introduction of vivax malaria in a temperate area, Russia, can serve as a case study for further research.
This study in Cabo Verde determined the G6PDd prevalence in the population, relatively low compared to other African countries. Further studies are needed to characterize and genotyping the G6PD variants in the country.
Africa needs to be prepared to deal with COVID-19, given the infectious potential of the disease and its capacity to undermine malaria control efforts. In addition to the shared vigilance that countries around the world should maintain, regions need to consider their local malaria epidemic and take additional measures for preparation.